# Emphasizing the Pharmacological Potentials of the Methanolic Extract of Wedelia montana: A Prominent Source of Veterinary Medicine

**Authors:** Millat Hossain Mesu, Md Ashraf Uddin Chowdhury, Mohammad Arman, Israt Jahan, Sourav Kumar Shill, Md. Al Mamun, Md. Jahirul Islam Mamun, Md. Abdul Alim, Md. Tanvir Chowdhury, S. M. Moazzem Hossen

PMC · DOI: 10.1155/vmi/1914665 · Veterinary Medicine International · 2026-01-28

## TL;DR

This study explores the medicinal potential of Wedelia montana, showing it has antioxidant, anti-parasitic, and pain-relieving properties, suggesting it could be a valuable source for veterinary medicine.

## Contribution

The study evaluates the pharmacological effects of Wedelia montana's methanolic extract using in vitro and in vivo models, highlighting its potential as a veterinary medicine source.

## Key findings

- MEWM showed potent antioxidant properties with an LC50 of 256.2 μg/mL.
- MEWM demonstrated significant anthelmintic and thrombolytic activity.
- MEWM exhibited antidepressant, anxiolytic, and analgesic effects in various in vivo models.

## Abstract

The research focused on Wedelia montana (Blume) Boerl because of its numerous medicinal applications. W. montana belongs to the Asteraceae family. This investigation is intended to analyze the phytochemical content of the methanol extract of W. montana (MEWM) and evaluate its biological features by utilizing in vitro and in vivo models. In vitro examinations determined antioxidant capability, cytotoxic, anthelmintic, and thrombolytic activity of the MEWM. Furthermore, in vivo research included testing for the effects of antidepressants (TST and FST), effects on anxiety (LDT, HBT, and EPM), activities of sedatives (HCT and OFT), and analgesic activities (formalin‐induced licking test and tail immersion test). Treatment with MEWM exhibited potent antioxidant properties, with a cytotoxicity test revealing an LC50 value of 256.2 μg/mL, in contrast to 142.28 μg/mL for the positive control. It also resulted in the shortest times for paralysis and mortality at the highest dosage in the anthelmintic assay and notable thrombolytic activity (p < 0.0001). Moreover, MEWM has shown considerable efficacy contingent upon the FST, TST, EPM, HBT, and LDT dose and sedative effects in the OFT and HCT. A 200 mg/mL dosage in the analgesic assessment had no significant impact on the tail immersion test. However, MEWM demonstrated substantial analgesic action in the formalin‐induced paw‐licking experiment (p < 0.0001). The data indicate that MEWM is a potential source of antioxidant, cytotoxic, anthelmintic, thrombolytic, antidepressant, anxiolytic, sedative, and antinociceptive compounds. Further research is necessary to comprehend its therapeutic benefits completely.

## Full-text entities

- **Diseases:** cytotoxic (MESH:D064420), paralysis (MESH:D010243), anxiety (MESH:D001007)
- **Chemicals:** Methanolic (-), formalin (MESH:D005557), methanol (MESH:D000432)
- **Species:** Wedelia montana [taxon 1205802]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12848604/full.md

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12848604/full.md

## References

52 references — full list in the complete paper: https://tomesphere.com/paper/PMC12848604/full.md

---
Source: https://tomesphere.com/paper/PMC12848604